Safety and efficacy of durvalumab (MEDI4736) in various solid tumors

被引：35

作者：

Yang, Hui ^{[1
,2
]}

Shen, Kai ^{[3
,4
,5
]}

Zhu, Chenjing ^{[3
,4
,5
]}

Li, Qingfang ^{[3
,4
,5
]}

Zhao, Yunuo ^{[2
]}

Ma, Xuelei ^{[3
,4
,5
]}

机构：

[1] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, West China Sch Med, Chengdu, Sichuan, Peoples R China

[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China

[4] Sichuan Univ, West China Hosp, Canc Ctr, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China

[5] Collaborat Innovat Ctr, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2018年 / 12卷

关键词：

durvalumab; solid cancers; adverse effects; efficacy; meta-analysis; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; NEGATIVE REGULATION; PD-L1; EXPRESSION; PHASE-I; BLOCKADE; IMMUNOTHERAPY; RECEPTOR; COMBINATION; TOXICITIES;

D O I：

10.2147/DDDT.S162214

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Introduction: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. Methods: A systematic search of PubMed, Embase, and related articles was performed. Safety data were analyzed using Comprehensive Meta-Analysis software program version 2. Ultimately. 17 studies with 1,529 patients were included in our analysis. Results: The major adverse events associated with durvalumab were pruritus and fatigue, while pruritus, increased alanine transaminase, and increased aspartate aminotransferase were common among patients treated with a combination of durvalumab and tremelimumab. Higher PD-L1 expression was associated with a superior objective response rate. Conclusion: Durvalumab is safe in patients with many solid cancers and, in combination with tremelimumab, it has a tolerable safety profile and is associated with improved prognosis. PD-L1 expression is a biomarker of the efficacy of durvalumab.

引用

页码：2085 / 2096

页数：12

共 52 条

[11] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[12] Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study [J].

Garassino, Marina ;

Vansteenkiste, Johan ;

Kim, Joo-Hang ;

Lena, Herve ;

Mazieres, Julien ;

Powderly, John ;

Dennis, Phillip ;

Huang, Yifan ;

Wadsworth, Catherine ;

Rizvi, Naiyer .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S10-S11

[13] Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study [J].

Garassino, Marina Chiara ;

Cho, Byoung-Chul ;

Kim, Joo-Hang ;

Mazieres, Julien ;

Vansteenkiste, Johan ;

Lena, Herve ;

Jaime, Jesus Corral ;

Gray, Jhanelle E. ;

Powderly, John ;

Chouaid, Christos ;

Bidoli, Paolo ;

Wheatley-Price, Paul ;

Park, Keunchil ;

Soo, Ross A. ;

Huang, Yifan ;

Wadsworth, Catherine ;

Dennis, Phillip A. ;

Rizvi, Naiyer A. .

LANCET ONCOLOGY, 2018, 19 (04) :521-536

[14] Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC [J].

Gibbons, D. L. ;

Chow, L. Q. ;

Kim, D-W. ;

Kim, S-W. ;

Yeh, T. ;

Song, X. ;

Jiang, H. ;

Taylor, R. ;

Karakunnel, J. ;

Creelan, B. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S79-S79

[15] Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients [J].

Higgs, Brandon W. ;

Morehouse, Chris ;

Streicher, Katie ;

Rebelatto, Marlon C. ;

Steele, Keith ;

Jin, Xiaoping ;

Pilataxi, Fernanda ;

Brohawn, Philip Z. ;

Blake-Haskins, John A. ;

Gupta, Ashok Kumar ;

Ranade, Koustubh .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[16] PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project [J].

Hirsch, Fred R. ;

McElhinny, Abigail ;

Stanforth, Dave ;

Ranger-Moore, James ;

Jansson, Malinka ;

Kulangara, Karina ;

Richardson, William ;

Towne, Penny ;

Hanks, Debra ;

Vennapusa, Bharathi ;

Mistry, Amita ;

Kalamegham, Rasika ;

Averbuch, Steve ;

Novotny, James ;

Rubin, Eric ;

Emancipator, Kenneth ;

McCaffery, Ian ;

Williams, J. Andrew ;

Walker, Jill ;

Longshore, John ;

Tsao, Ming Sound ;

Kerr, Keith M. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :208-222

[17] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

Horvat, Troy Z. ;

Adel, Nelly G. ;

Thu-Oanh Dung ;

Momtaz, Parisa ;

Postow, Michael A. ;

Callahan, Margaret K. ;

Carvajal, Richard D. ;

Dickson, Mark A. ;

D'Angelo, Sandra P. ;

Woo, Kaitlin M. ;

Panageas, Katherine S. ;

Wolchok, Jedd D. ;

Chapman, Paul B. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) :3193-+

[19] PD-L1 Blockade for Cancer Treatment: MEDI4736 [J].

Ibrahim, Ramy ;

Stewart, Ross ;

Shalabi, Aiman .

SEMINARS IN ONCOLOGY, 2015, 42 (03) :474-483

[20] Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. [J].

Kelley, Robin Kate ;

Abou-Alfa, Ghassan K. ;

Bendel, Johanna C. ;

Kim, Tae -You ;

Borad, Mitesh J. ;

Yong, Wei-Peng ;

Morse, Michael ;

Kang, Yoon-Koo ;

Rebelatto, Marlon ;

Makowsky, Mallory ;

Xiao, Feng ;

Morris, Shannon R. ;

Sangro, Bruno .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 6 →